New cocktail targets Hard-to-Treat stomach cancer
NCT ID NCT07334431
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a combination of three drugs (fruquintinib, trastuzumab, and chemotherapy) as a first treatment for people with HER2-positive advanced stomach or gastroesophageal junction cancer. The goal is to see if the combo is safe and can shrink tumors or slow cancer growth. About 45 participants will take part in this early-phase trial at one hospital in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fruquintinib, trastuzumab, oxaliplatin, capecitabine
What this could lead to
If it works, this could offer a new first-line treatment option for people with HER2-positive advanced stomach cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong
This is an early-phase, small study (45 people) at one center. The drug combo may cause significant side effects, and results may not apply to everyone. Success is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University)
RECRUITINGZhengzhou, Henan, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact